ABOUT US
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
VIDEOS
FEATURED PRODUCTS
-
MabSelect™ VL resin — protein L resin for affinity capture of antibody Fabs, bispecifics, and other variants containing a kappa light chain.
-
Supplements cell culture with amino acids, vitamins, and glucose and manufactured to meet cGMP manufacturing standards and QC specifications.
-
ÄKTA™ chromatography systems can handle both simple and complex purification tasks and accelerate daily routines. All systems are controlled by UNICORN™ software, a common control platform and user interface for all scales of operation.
-
Cytiva provides filtration solutions and support for integrated bioprocessing applications at every step and every scale of the drug development, validation and manufacturing process.
-
We offer a range of systems, accessories, and reagents for label-free analysis using microcalorimetry or surface plasmon resonance (SPR). These techniques provide information-rich, real time data without the use of labels.
-
Accelerate your biomanufacturing capacity with purpose-built modules
KUBio™ box modular bioprocessing environments are designed to help biopharmaceutical manufacturers bring high-quality biopharmaceuticals to market more quickly. By reducing typical design and construction times and streamlining process execution, they support future expansion and replication needs. Available KUBio™ box modular environments for biosafety levels 1 and 2 (BSL-1 and BSL-2) can be delivered in 10 to 15 months for implementation inside existing infrastructure. The result? Reduced project risk, accelerated delivery of next-gen therapies, and greater flexibility at different production scales and product technologies.
-
Transform your space to fit your needs
Configurable FlexFactory™ biomanufacturing process trains can help scientists better control the production and processing of different viral vectors and new modalities—all within the same space. Plan your agile manufacturing strategy with greater efficiency and integration to address current and future capacity needs.
-
Single-use, automated filtration system designed to deliver robust process control during the clarification/harvest step.
-
ÄKTA flux is a semi-automated tangential flow filtration/cross flow filtration system for concentration and diafiltration as well as cell harvest and clarification.
-
ÄKTA readyflux™ XL is the latest addition to our single-use filtration family. The system’s broad flow-rate range with a low hold-up volume and multiple filtration-control features provide versatility.
BROCHURES AND DATASHEETS
- Antibody Production: Scale-Up Menu
- An Automated Filtration And Bulk Filling System
- Single-Use Automated Virus Filtration System
- A Single-Use, Automated Filtration System For Robust Process Control
- Filtration Hardware
- An Automated Single-Use Filtration System For Crossflow Filtration
- An IoT Solution For A Reliable, Real-Time Informed Diagnosis
- A Flexible Service Model With Rapid Response And Access To Knowledge
- Online Service Solutions For Optimal Performance Of Your Instruments
- Single‑Use Filtration System For Pilot‑ And Small‑Scale Manufacturing
WEBINARS
APPLICATION NOTES
- Production Of A Highly Concentrated Monoclonal Antibody
- Extractables In Single-Use Systems Used In ADC Manufacturing
- TFF Cassettes With 100 kDa Membranes For RNA And LNP Applications
- Media And Buffer Mixing Using The Xcellerex™ Magnetic Mixer
- Determining The Power Numbers For A Single-Use Mixing System
- Adapting Single-Use Chromatography To Manufacturing Scale
- Developing A Large-Scale Tangential Flow Filtration Process
- Bulk Filling Of Drug Substance | Accurate Aliquoting
- Sterilizing Grade Filter Performance With Biologic Drugs
- Developing A HIC Polishing Step For The Removal Of mAb Aggregates
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Learn about the partnership between the Prairie HUB and Cytiva to create RNA vaccines to target potential pandemic viruses with the aim of redefining global pandemic preparedness.
-
One of the key concerns for many biopharmaceutical companies is minimizing environmental impact. Learn about additive manufacturing and the significant advantages it offers to biomanufacturers.
-
Gain insight into the current landscape of filling and late-stage manufacturing from a survey of 78 professionals from top companies in the industry.
-
One way to address risk related to product quality is by implementing a Question-based Review approach. Read on to learn about this approach and its advantages.
-
Given the numerous stakeholders involved throughout a product's lifecycle and the limited direct control companies have, how can biopharma organizations effectively measure and manage Scope 3 emissions?
-
What actions are biopharma leaders worldwide taking to enhance sustainability? What challenges are they encountering? And how can the broader industry learn from the companies paving the way?
-
What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?
-
Explore some of the biggest obstacles companies are encountering and what is already being done to move the industry closer to significant sustainability progress and environmental achievements.
-
Explore key insights into how sustainability efforts are influencing business outcomes from a survey that collected data from 800 pharma and biopharma executives across 18 countries.
-
Learn about the changes introduced in the latest revision to EU GMP Annex 1, and gain insight into the components that should be part of a PUPSIT risk assessment.
NEWS
- Cytiva Opens Cell Culture Center Of Excellence In Massachusetts
- Cytiva Strengthens Cell Line Development With CEVEC Acquisition
- Cytiva Expanding US Operations
- Cytiva Attains Business Continuity Management System ISO Certification
- Cytiva Acquires GoSilico To Strengthen Digital Capabilities In Bioprocessing
- Cytiva Delivers KUBio To Lonza
- Cytiva's Fibro PrismA Technology Accelerates mAb Purification In LifeArc's Covid-19 Research
- New KUBio Box For Viral Vectors Boosts Gene Therapy Manufacturing
- Lonza To Establish Strategic Biomanufacturing Base In China Using GE Healthcare Solution
- Rentschler Biotechnologie Expands European Manufacturing Capabilities With GE Healthcare Life Sciences Bioprocess Technologies